drugset / Trial / NCT06957223
Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.
Timeline
- Start
- 2025-05-06
- Primary completion
- 2025-11-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | — | Oral |
| Subject | Dextromethorphan | Unknown | — | Oral |
| Comparator | Escitalopram | Small molecule | — | Oral |
| Comparator | Sertraline | Small molecule | — | Oral |